Brokers Issue Forecasts for TENX Q1 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Roth Capital issued their Q1 2025 earnings estimates for Tenax Therapeutics in a note issued to investors on Wednesday, November 13th. Roth Capital analyst J. Aschoff anticipates that the specialty pharmaceutical company will post earnings of ($0.18) per share for the quarter. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($6.62) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.20) EPS.

TENX has been the subject of a number of other reports. Leerink Partners began coverage on Tenax Therapeutics in a report on Thursday, October 24th. They set an “outperform” rating and a $16.00 price target for the company. Guggenheim assumed coverage on shares of Tenax Therapeutics in a research report on Monday, October 14th. They set a “buy” rating and a $16.00 price target on the stock. Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a research note on Thursday, October 24th. William Blair started coverage on shares of Tenax Therapeutics in a research report on Monday, September 30th. They set an “outperform” rating for the company. Finally, StockNews.com assumed coverage on Tenax Therapeutics in a research report on Thursday, September 26th. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.00.

Tenax Therapeutics Stock Down 1.4 %

TENX opened at $4.87 on Friday. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $41.92. The firm’s 50-day simple moving average is $3.99 and its 200-day simple moving average is $3.70.

Hedge Funds Weigh In On Tenax Therapeutics

Several hedge funds have recently made changes to their positions in the business. Sphera Funds Management LTD. acquired a new stake in Tenax Therapeutics in the 3rd quarter valued at $101,000. Stonepine Capital Management LLC bought a new position in Tenax Therapeutics in the third quarter valued at approximately $173,000. Finally, Vestal Point Capital LP acquired a new position in shares of Tenax Therapeutics during the 3rd quarter worth approximately $288,000. 1.67% of the stock is owned by institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.